# B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

> **NCT03931421** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CAR-T treatment

## Key facts

- **NCT ID:** NCT03931421
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-31
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03931421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03931421, "B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT03931421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*